1. Scrip
  2. >>R&D

Immuno-Oncology: Sneak Peek Of Preclinical Candidates Waiting In The Wings

 
• By Rachel L Meighan-Mantha

Which immuno-oncology candidates are poised to begin their first-in-human clinical trials? How many sponsors already have partners or collaborators? What oncology indications have been proposed? And where will these trials take place? Citeline's Rachel L. Meighan-Mantha has the data.

Ticket

Plenty of excitement has been generated recently in the immuno-oncology sphere by the accelerated [Food & Drug Administration] approvals in May 2016 for Bristol-Myers Squibb Co.’s PD-1 antagonist, Opdivo (nivolumab), in relapsed/refractory classical Hodgkin’s lymphoma and for Genentech Inc.’s PD-L1 antagonist, Tecentriq (atezolizumab), in relapsed/refractory, advanced or metastatic urothelial carcinoma. Those approvals, along with an abundance of data reported at the ASCO 2016 annual meeting on immuno-oncology (a query of the ASCO 2016 annual meeting abstracts using the keywords related to immune-oncology resulted in almost 1500 abstracts), seems to have spurred multiple investment deals in June and already in July, according to Strategic Transactions.

But which immuno-oncology candidates are poised to begin their first-in-human (FIH) clinical trials? How many sponsors already have partners or collaborators? What oncology indications have been proposed? And where will these trials take place? Informa’s Pharma Intelligence suite of services can offer some clues

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

More from Scrip

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.